Proton pump inhibitors use and risk of inflammatory bowel diseases: a meta-analysis of observational studies

Sanjana Aditya Shastri, Raveena Kantamneni, Muhammed Rashid, Viji Pulikkel Chandran, Ramadugula Suhita, Izwath Begum, Sreedharan Nair, Girish Thunga

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Background and objective. Proton Pump Inhibitors (PPIs) reduce gastric acid production and they are indicated for myriad gastrointestinal conditions. Prolonged use of PPI has been linked to the risk of inflammatory bowel disease (IBD) though this fact is not well established. We aimed to conduct a systematic review and metaanalysis to estimate the risk of IBD occurrence with PPI use. Methodology. The databases such as PubMed, Scopus, and Cochrane Library were accessed from inception to December 2020. Additionally, the bibliographic search and a random search in Google, Google Scholar, and ResearchGate were performed to find additional sources. The observational studies estimating the risk of IBD following the use of PPI, published in the English language were considered for this review. The methodological quality of included studies was assessed using the Modified Downs and Black checklist. Results. Eight out of 2038 studies with 157,758 participants were included in this meta-analysis. A significantly higher risk of IBD (adjusted odds ratio [aOR] 2.43; 95% Confidence Interval [CI] 1.18-5.02; P=0.02; n=6) was observed in participants taking PPIs for any indication. Moreover, a significant association was observed between PPI exposure on the different types of IBD such as ulcerative colitis and Crohn’s disease together (aOR: 3.60; 95% CI: 1.10-11.74), collagenous colitis (OR: 4.73; 95% CI: 1.99-11.22) and lymphocytic Colitis (OR: 3.77; 95% CI: 2.91-4.87), but not with ulcerative colitis (P=0.47) and microscopic colitis (P=0.07) alone. Similarly, a significant association was observed among Europeans (aOR: 3.98; 95% CI: 2.36-6.71), but not with North American (aOR: 0.48; 95% CI: 0.01-26.71) studies. Overall the study quality was good. Conclusion. The current evidence indicates that exposure to PPI is significantly associated with increased risk of IBD. Further, adequately powered studies from various parts of the world are needed for better quantification and generalizability of our findings.

Original languageEnglish
Pages (from-to)357-369
Number of pages13
JournalMedicine and Pharmacy Reports
Issue number4
Publication statusPublished - 2022

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Proton pump inhibitors use and risk of inflammatory bowel diseases: a meta-analysis of observational studies'. Together they form a unique fingerprint.

Cite this